RCKT News and Press, Rocket Pharmaceuticals Inc. From 10/19/23

2023-10-19 01:20:00 ET Summary Baron Health Care Fund invests in companies engaged in the research, development, production, sale, delivery, or distribution of products and services related to the health care industry. The Fund trailed the Benchmark by 217 basis points this quarte...

2023-10-02 08:40:28 ET More on Rocket Pharma Rocket Pharmaceuticals: Update On RP-A501 Strengthens Bullish Outlook Rocket Pharmaceuticals: Soaring On Pivotal Danon Disease Study Agreement - More Upside Ahead? Rocket Pharmaceuticals: Thriving Gene Therapy With Multipl...

Prescription Drug User Fee Act (PDUFA) target action date is March 31, 2024 RP-L201 has received FDA Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric, Fast Track and Orphan Drug designations; Rocket eligible for Priority Review Voucher, if RP-L201 is approved Rock...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in ...

2023-09-23 09:45:00 ET Intellia Therapeutics (NASDAQ: NTLA) and Rocket Pharmaceuticals (NASDAQ: RCKT) are gene-editing biotechs that want to offer what few others can: cures for hereditary afflictions that have so far proved beyond the reach of medical science. But for the m...

2023-09-21 07:30:00 ET Summary Rocket Pharmaceuticals achieves a significant milestone in their RP-A501 therapy for Danon Disease, strengthening their position in the gene therapy industry. RP-A501 aims to restore normal cardiac function and offer a lifetime of benefit to patients...

2023-09-18 07:30:00 ET With Rocket Pharmaceuticals ' (NASDAQ: RCKT) shares surging 38% higher on Sept. 13, it's clear that the stock has its enthusiastic supporters. The rare disease drug developer just announced that the Food and Drug Administration (FDA) gave it the go-ahead t...

2023-09-14 09:40:10 ET Summary Rocket Pharmaceuticals announced yesterday it had reached agreement with the FDA on a potentially pivotal study of in vivo gene therapy candidate RP-A501. The drug candidate has faced a long journey to get to this point - now a historic opportunity a...

2023-09-13 14:16:14 ET Gainers: Avalo Therapeutics ( AVTX ) +56% . ZyVersa Therapeutics ( ZVSA ) +41% . Rocket Pharmaceutical ( RCKT ) +35% . Vigil Neuroscience ( VIGL ) +31% . Aspira Women's Health ( AWH ) +27% . Novo Integr...

2023-09-13 11:56:54 ET Shares of Rocket Pharmaceuticals (NASDAQ: RCKT) were up by more than 36% as of 11 a.m. on Wednesday after the clinical-stage biotech company said late Tuesday that the Food and Drug Administration (FDA) had signed off on its phase 2 pivotal trial for a tre...